Denali shares soar on potential $2.4 billion Parkinson's, Alzheimer's deal with Biogen

The deal includes a $560 million upfront payment and $465 million equity stake in the South San Francisco-based trailblazer in experimental neurodegenerative disease drugs.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.